OFEV 100 MG
NINTEDANIB (NINTEDANIB ESILATE) : 100 MG · DIN 02443066 · BOEHRINGER INGELHEIM (CANADA) LTD LTEE
Health Canada status: MARKETED
What is OFEV?
OFEV 100 MG contains NINTEDANIB (NINTEDANIB ESILATE) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02443066, held by BOEHRINGER INGELHEIM (CANADA) LTD LTEE, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Jun-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02443066 |
|---|---|
| Brand name | OFEV |
| Generic / active ingredient | NINTEDANIB (NINTEDANIB ESILATE) : 100 MG |
| Manufacturer | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
| Strength | 100 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EX09 NINTEDANIB |
| AHFS class | 48:02.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Jun-2015 |
| Original market date | 2015-06-29 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code L01EX09 NINTEDANIB. 5 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-NINTEDANIB | 100 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02526891 |
| AURO-NINTEDANIB | 150 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02526905 |
| JAMP NINTEDANIB | 150 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02540762 |
| OFEV | 150 MG | CAPSULE | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | DIN 02443074 |
| EUGIA-NINTEDANIB | 100 MG | CAPSULE | EUGIA PHARMA INC. | APPROVED | DIN 02547511 |
| EUGIA-NINTEDANIB | 150 MG | CAPSULE | EUGIA PHARMA INC. | APPROVED | DIN 02547538 |
Who else supplies NINTEDANIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NINTEDANIB appears in 145 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.